Written by user

Thursday, 03 June 2010 15:44

Fatpipe Networks India Limited IPO

Fatpipe Networks India Limited, owned by DR. RAGULA BHASKAR, is the inventor and multiple patents holder of technology that provides the highest levels of WAN optimization, reliability, security, and bandwidth management.

Fatpipe's core technology, router clustering, involves patented and patent-pending methods that provide the highest levels of optimization, reliability, security and acceleration of Wide Area Networks (WANs) and enable high-speed data transfer through multiple lines, multiple ISPs, and backbones over WANs with seamless reassembly of data streams. Fatpipe technology affords companies, that run mission critical WAN applications over any type of infrastructure, automatic and dynamic failover of a downed data line due to a WAN component, line or service failure.

Company holds 7 patents on a technology called "Router-Clustering," which enables customers to obtain highly redundant and fast Internet/WAN access. FatPipe sells its products worldwide through a network of 2 authorized distributors and over 500 resellers. FatPipe is proposing to expand its operations to China, Singapore, South Africa, Kenya, Nigeria, Argentina, Belgium, Germany, France, Eastern Europe and Australia. Fatpipe will be setting up a wholly owned subsidiary in the US to expand US operations and to solicit government business.

Issue Detail:
  • »» Issue Open: Jun 07, 2010 - Jun 09, 2010
  • »» Issue Type: 100% Book Built Issue IPO
  • »» Issue Size: Equity Shares of Rs. 10
  • »» Issue Size: Rs. 49.00 Crore
  • »» Face Value: Rs. 10 Per Equity Share
  • »» Issue Price: Rs. 82 - Rs. 85 Per Equity Share
  • »» Market Lot: 70 Shares
  • »» Minimum Order Quantity: 70 Shares
  • »» Listing At: BSE, NSE
Parabolic Drugs Limited IPO

Parabolic Drugs Limited is in the business of manufacturing Active Pharmaceutical Ingredients (API's) and API intermediates. APIs, also known as 'bulk drugs' or 'bulk actives' are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

Companies product portfolio comprises 42 APIs and 7 API intermediates which are marketed domestically and exported.

Company own and operate two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. Company is in the process of setting up a custom synthesis and research and development (R&D) center at Barwala, Haryana.

Objects of the Issue:
The objects of the issue are:
  • 1. Multi-purpose block III at Derabassi;
  • 2. Sterile Cephalosporin Plant (Derabassi);
  • 3. Establishment of Chachrauli Plant;
  • 4. Custom Synthesis & Manu. Site II at IT Park (Panchkula);
  • 5. Repayment / Prepayment of identified loan facility;
  • 6. General corporate purposes.
Issue Detail:
  • »» Issue Open: Jun 14, 2010 - Jun 17, 2010
  • »» Issue Type: 100% Book Built Issue IPO
  • »» Issue Size: Equity Shares of Rs. 10
  • »» Issue Size: Rs. 200.00 Crore
  • »» Face Value: Rs. 10 Per Equity Share
  • »» Issue Price: Rs. - Rs. Per Equity Share
  • »» Market Lot:
  • »» Minimum Order Quantity:
  • »» Listing At: BSE, NSE

Last Updated on Tuesday, 15 June 2010 11:18